Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24286738.
- Also identified by DOI 10.1016/j.hcl.2013.09.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although the mechanism is unknown, Btx-A injection may be an effective, localized, nonsurgical treatment option without addictive properties or systemic side effects for the treatment of ischemic digits. Clinical research supports the safety and efficacy of injection of Btx-A for the treatment of Raynaud phenomenon.
Medical subject headings
- Botulinum Toxins, Type A
- Neuromuscular Agents
- Raynaud Disease